Duo Oncology
@DuoOncology
Followers
10
Following
1
Media
2
Statuses
19
On a mission to develop therapies for patients with stroma-rich tumors
Joined October 2020
USPTO has granted a patent on the chemistry for Duo Oncology's lead product and pipeline. The issued patent does not expire until October 2040.
0
0
1
.Duo Oncology is please to announce an new NIH STTR grant award.
duooncology.com
NIH STTR Award Funds Additional Studies Exploring Improved Duration of Treatment with DUO-207 in Mice and Dogs.
0
0
0
Duo Oncology Selected for Prestigious NCI SBIR Investor Initiatives.
duooncology.com
The National Cancer Institute has selected Duo Oncology for its elite Investor Initiative Program
0
0
0
The Galien Foundation, dedicated to innovation to improve the human condition, selects Duo Oncology as Nominee for 2024 Best Startup. (Read more at
0
2
1
.Duo Oncology receives additional NIH support to expand its pipeline.
duooncology.com
Duo Oncology, a life science company developing ultra-small cancer nanomedicines, is pleased to announce that it is one of twenty companies selected for the National Institutes of Health’s Entrepre...
0
1
0
Eckuity Capital Closes $150 Million Fund and Appoints New Partner - Top Clinical Oncologist, Dr Victoria Manax Rutson Duo is pleased to continue working with Dr. Manax and says "Kudos Victoria on becoming a Partner at Eckuity!".
prnewswire.com
/PRNewswire/ -- Eckuity Capital, a New York and London-based growth and venture capital investor, has appointed Dr Victoria Manax Rutson (Dr Manax) as a new...
0
0
0
Duo Oncology Founders Continue Nanomedicine Research with $2M Award from the National Cancer Institute.
duooncology.com
Dr. Song Li, founder of Duo Oncology, receives NCI award to develop chemo/immunotherapy nanomedicines.
0
1
0
Duo Oncology Founders Publish on New Ultrasmall Nanomedicine Product
duooncology.com
Drs. Song Li and Jingjing Sun Publish in Materials Today on Novel Ultrasmall Nanomedicine Immunotherapy.
0
0
0
Duo Oncology unveils new website and branding to emphasize mission in cancer medicine.
duooncology.com
0
0
1
Duo Oncology has received a favorable written option from its Pre-IND meeting with the FDA. The agency response confirms a clear roadmap for development of DUO-207 as a first-line therapy for pancreatic cancer and other solid malignancies.
0
0
0
Press Release - National Event Provided Life Science Startup Businesses Unprecedented Access to Venture and Investment Industry - Announcing Top 6 Applicants
0
0
0
EMA Awards Lead Product DUO-207 Orphan Designation for Pancreatic Cancer.
shoutout.wix.com
PITTSBURGH (PRWEB) February 22, 2022 – Duo Oncology, a life science company pioneering ultra-small cancer nanomedicines, is pleased to announce that the European Medicines Agency (EMA) has granted...
0
2
1